A signal that tracks closely with what patients can do with their hands.
In a quiet neuromuscular clinic in Sydney, researchers asked a deceptively simple question: is there a better way to measure how spinal muscular atrophy is eating away at the nervous system? The answer they found may lie in a type of electrical signal most clinicians have barely considered for this disease.
Spinal muscular atrophy, or SMA, is caused by mutations in the SMN1 gene that leave the body unable to produce enough of a protein the motor neurons depend on to survive. Those neurons — the ones in the spinal cord that tell muscles to move — gradually deteriorate, and with them goes strength, mobility, and independence. The disease is lifelong, and while treatments like Spinraza and Evrysdi have changed the landscape in recent years, tracking how the disease progresses in any given patient remains frustratingly imprecise.
The standard tool for that job is something called the compound muscle action potential, or CMAP — a measurement of how strongly a muscle responds electrically when its nerve is stimulated. It's useful, but it has a known weakness: it doesn't always accurately reflect the actual loss of nerve fibers, and its readings can shift depending on where exactly the electrode is placed. Researchers at the Neuromuscular Clinic in Sydney turned their attention to a different kind of signal entirely: far-field potentials, or FFPs.
Far-field potentials are electrical signals recorded at the skin's surface after nerve stimulation, but unlike CMAP, they're less sensitive to electrode placement and have already shown promise as a diagnostic and prognostic marker in ALS, another motor neuron disease. The Australian team wanted to know whether FFPs could do the same work in SMA. They recruited 13 people with SMA, 19 with ALS, and 19 healthy volunteers, then stimulated the ulnar nerve at the wrist and recorded the resulting signals.
The numbers told a clear story. In healthy participants, FFP amplitude averaged 8.4 millivolts. In the SMA group, it was 4.1 millivolts — roughly half. The ALS patients fell in between at 6.2 millivolts, and the difference between the SMA and ALS groups was not statistically significant. CMAP told a similar directional story but was less precise: SMA patients averaged 4.4 millivolts, compared to 7.9 in ALS patients and 11.6 in healthy controls.
The SMA participants in the study were mostly women, with a median age of 33 and a median disease duration of more than 28 years. The majority had SMA type 3, the milder ambulatory form, though some had type 2. Four could still walk at the time of the study, six could sit but not walk, and three could no longer sit independently. About a third had never received a disease-modifying treatment; the rest were on either Spinraza or Evrysdi.
What made the FFP findings particularly compelling was how tightly the signal tracked with actual function. Higher FFP amplitude correlated with better upper-limb performance, finer motor control, and less overall impairment. When the researchers ran statistical models to identify which measures independently predicted hand and arm function — as scored by the Revised Upper Limb Module — FFP came out on top. CMAP did not make the cut as an independent predictor. The relationship between FFP and upper-limb scores was also stronger than the one between CMAP and those same scores.
The researchers published their findings in the journal Muscle & Nerve, arguing that FFP amplitude deserves a place in clinical assessments and drug trials as a reliable marker of motor neuron health. They were careful to note the study's limits: thirteen SMA participants is a small cohort, and the findings need replication in larger groups before FFP can be considered a validated endpoint.
Still, the direction is clear. As SMA treatments grow more sophisticated and the need to measure their effects more precisely becomes more urgent, a signal that can be captured with surface electrodes at the wrist — and that tracks closely with what patients can actually do with their hands — is exactly the kind of tool clinicians have been looking for. The next step is building the evidence base to put it to work.
Notable Quotes
Incorporating FFP amplitude measurements into clinical assessments and trials may enhance disease monitoring and provide a reliable marker for tracking disease progression.— Study authors, published in Muscle & Nerve
The Hearth Conversation Another angle on the story
Why does it matter so much to have a better way to track SMA progression? Don't doctors already have tools for that?
They do, but the existing tools have real gaps. CMAP, the standard measure, doesn't always catch nerve fiber loss accurately, and it's sensitive to how precisely you place the electrode. When you're trying to measure subtle changes over years, that imprecision adds up.
And far-field potentials solve that problem?
They're less sensitive to electrode placement, which makes them more consistent. And in this study, they turned out to be a stronger predictor of actual hand and arm function than CMAP was. That's the key finding — it's not just a different signal, it's a more informative one.
The amplitude in SMA patients was about half that of healthy people. Is that gap meaningful in practice?
It's striking. Four-point-one millivolts versus eight-point-four is a substantial difference, and it correlated with real functional differences — whether someone could walk, sit, use their hands. The signal isn't just a number; it maps onto lived experience.
The ALS patients were also in the study. Why compare SMA to ALS?
FFPs were already being used in ALS research, so ALS served as a kind of reference point — a disease where the tool had already shown value. The fact that SMA and ALS patients had statistically similar FFP amplitudes suggests the signal is picking up on a shared underlying process: motor neuron deterioration.
Most of the SMA participants had been living with the disease for over 28 years. Does that long duration affect how we interpret the results?
It's worth sitting with. These are people who've carried this disease for most of their lives, and yet the signal still tracked meaningfully with their current function. That suggests FFP is capturing something real about the state of the nervous system right now, not just historical damage.
What would it take to actually get FFP into clinical trials?
Larger studies, mostly. Thirteen participants is enough to generate a hypothesis, not enough to validate a biomarker for regulatory purposes. Researchers would need to show the same relationships hold across bigger, more diverse groups — and ideally, that changes in FFP over time predict clinical outcomes.